Abbott Laboratories stock (US0028241000): Q4 earnings call set for Jan. 22

Abbott Laboratories has scheduled its fourth-quarter 2025 earnings release for Thursday, Jan. 22, 2026, before the market opens, followed by a live conference call at 8:00 a.m. Central Time. The webcast will be available on the company's investor relations site. This comes after the stock hit a 52-week low of $81.97 recently, closing at $82.58 amid legal challenges over infant formula cases, Stock Titan as of Jan. 5, 2026.

As of: 13.05.2026

By the editorial team – specialized in equity coverage.

Abbott Laboratories: core business model

Abbott Laboratories operates as a diversified healthcare company focused on diagnostics, medical devices, nutritional products, and established pharmaceuticals. The firm generates revenue through four main segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. In recent quarters, diagnostics have been a growth driver, particularly cardiovascular and diabetes care tests. Abbott's business model emphasizes innovation and global reach, with significant exposure to the US market where it holds strong positions in point-of-care testing.

Main revenue and product drivers for Abbott Laboratories

Diagnostics represented a key revenue pillar, with products like the Alinity systems and FreeStyle Libre continuous glucose monitoring driving sales. Nutritional products, including infant formula under brands like Similac, contribute steadily despite ongoing legal scrutiny from past contamination issues. Medical devices, such as stents and structural heart solutions, target high-growth areas. For Q1 2026, Abbott reported market share leadership in its sector, per CSIMarket as of Q1 2026. US investors track these segments for their ties to aging demographics and chronic disease trends.

Industry trends and competitive position

The medical devices sector sees robust demand from diabetes management and cardiovascular tech. Abbott competes with Johnson & Johnson and Eli Lilly, holding 4.15% market share in Q1 2026 versus JNJ's 8.86%, according to CSIMarket as of Q1 2026. Investments like the $55 million in NVision's Series B highlight Abbott's venture push into ophthalmology tech, bolstering its innovation pipeline.

Why Abbott Laboratories matters for US investors

Abbott's NYSE listing and heavy US revenue exposure make it a staple for healthcare portfolios. Its diagnostics and device franchises align with US trends in telehealth and chronic care, offering stability amid economic shifts. Recent guidance for FY 2026 EPS of $5.380-$5.580 underscores resilience, per analyst updates.

Conclusion

Abbott Laboratories approaches its Q4 2025 earnings with a solid portfolio in diagnostics and devices, tempered by legal headwinds in nutrition. The upcoming Jan. 22 call will provide insights into full-year performance and outlook. US investors monitor these updates for sector leadership signals.

Disclaimer: This article does not constitute investment advice. Stocks are volatile financial instruments.